



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/584,411      | 05/31/2000  | Richard A. Shimkets  | 15966-552 (Cura-52) | 6088             |

30623 7590 09/02/2003

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY  
AND POPEO, P.C.  
ONE FINANCIAL CENTER  
BOSTON, MA 02111

EXAMINER

ULM, JOHN D

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1646

DATE MAILED: 09/02/2003

25

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/584,411

Applicant(s)

SHIMKETS ET AL.

Examiner

John D. Ulm

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE \_\_\_\_ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☐ Claim(s) \_\_\_\_ is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_.
- 4) ☐ Interview Summary (PTO-413) Paper No(s) \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

1) Claims 39 to 51 are pending in the instant application. Claims 1 to 38 have been canceled and claims 39 to 51 have been added as requested by Applicant in Paper Number 23, filed 11 August of 2003.

2) The disclosure is objected to because of the following informalities:

There is text missing from line 5 on page 1 of the specification. See the text "and USSN 60/\_\_\_\_\_".

Pages 6 to 15 of the specification, as filed, did not have an adequate top margin. 37 C.F.R. § 1.52(b) requires that the top of each page of the application must have a margin of at least approximately 3/4 inch (2 cm.). This margin is needed to prevent possible mutilation of text when the papers are punched for insertion in a file wrapper. Text has been deleted from each of these pages in the instant specification because of the lack of an adequate top margin.

The text in line 7 on page 77 of the instant specification refers to "a NOV12 polypeptide" in a context which would suggest that Applicant intended to refer to a NOV11 polypeptide.

Appropriate correction and/or clarification is required.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

3) Claims 39 to 51 are rejected under 35 U.S.C. § 101 because they are drawn to an invention with no apparent or disclosed specific and substantial credible utility. The instant application has provided a description of isolated DNA encoding twenty three different human proteins and the proteins encoded thereby. The instant application does not disclose a specific biological role for any one of these proteins or

its significance to a particular disease, disorder of physiological process which one would wish to manipulate for a desired clinical effect.

The instant application discloses that the protein identified on page 77 therein as "NOV11" (SEQ ID NO:22), which is encoded by the elected invention, is potentially related to heregulin because there are certain structural similarities between SEQ ID NO:22 and the amino acid sequence of human gamma heregulin. Because the amino acid sequence of NOV11 and that of human gamma heregulin are only 55% identical, one of ordinary skill would not reasonably conclude that NOV11 is an allelic variant of human gamma heregulin. Whereas the instant specification identifies prospective roles for gamma heregulin and the tenascin proteins related thereto in certain aspects of tumor development, there is no evidence or sound scientific reasoning of record that supports a conclusion that NOV11 plays a similar role in these processes. This is particularly true in light of Applicant's disclosure that NOV11 is not a secreted protein whereas gamma heregulin and the tenascin proteins are described in the specification as "extracellular matrix proteins". One of ordinary skill in the art of molecular biology, therefore, would not reasonably conclude that NOV11 is functionally analogous to gamma heregulin or the tenascin proteins.

It is clear from the instant specification that NOV11 is what is termed an "orphan protein" in the art. This is a protein whose cDNA has been isolated because of its similarity to known proteins. There is little doubt that, after complete characterization, NOV11 may be found to have a specific and substantial credible utility. This further characterization, however, is part of the act of invention and until it has been undertaken Applicant's claimed invention is incomplete. The instant situation is directly analogous to that which was addressed in *Brenner v. Manson*, 148 U.S.P.Q. 689 (Sus. Ct, 1966), in which a novel compound which was structurally analogous to other compounds which were known to possess anti-cancer activity was alleged to be potentially useful as an anti-tumor agent in the absence of evidence supporting this utility. The court expressed

the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of "useful" as it appears in 35 U.S.C. § 101, which requires that an invention must have either an immediately obvious or fully disclosed "real world" utility. The court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility", "[u]nless and until a process is refined and developed to this point-where specific benefit exists in currently available form-there is insufficient justification for permitting an applicant to engross what may prove to be a broad field", and "a patent is not a hunting license", "[i]t is not a reward for the search, but compensation for its successful conclusion."

The instant claims are drawn to an isolated nucleic acid encoding a protein of as yet undetermined function or biological significance. Until some actual and specific significance can be attributed to that protein which identified in the specification as "NOV11", or the gene encoding then, the instant invention is incomplete. The protein of the instant invention is a compound which is structurally analogous to proteins which are known in the art as heregulins. In the absence of a knowledge of the natural functions or biological significance of this particular protein, there is no immediately obvious patentable use for it. To employ a protein of the instant invention in the identification of substances that inhibit its activity is clearly to use it as the object of further research which has been determined by the courts to be a non-patentable utility. Since the instant specification does not disclose a credible, substantial and specific "real world" use for the NOV11 protein described there then the claimed invention is incomplete and, therefore, does not meet the requirements of 35 U.S.C. § 101 as being useful.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the

art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4) Claims 39 to 51 are also rejected under 35 U.S.C. 112, first paragraph.

Specifically, since the claimed invention is not supported by either a credible substantial and specific asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

5) Claims 40 and 50 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The instant specification does not contain an adequate written description of "a mature form" of a polypeptide comprising the amino acid sequence of SEQ ID NO:22. In the decision of *The Regents of the University of California v. Eli Lilly and Company*, 43 USPQ2d 1398

(CAFC 1997), the court held that:

"To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." *Lockwood v. American Airlines, Inc.* , 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." *Lockwood* , 107 F.3d at 1572, 41 USPQ2d at 1966.

Art Unit: 1646

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel*, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." *Id.* at 1170, 25 USPQ2d at 1606. Because the instant specification does not identify that structural feature or combination of features which distinguish a naturally occurring variant of the disclosed protein from one which has been intentionally modified, the specification fails to provide a precise description of the claimed genus of proteins encompassed by the limitation "a naturally occurring allelic variant of SEQ ID NO:24" "by structure, formula, chemical name, or physical properties" as required by the first paragraph of 35 U.S.C. § 112.

Because the instant specification does not disclose how a mature form of a protein comprising the amino sequence of SEQ ID NO:22 differs structurally from an immature(?) form, it does not provide an adequate written description of the claimed invention.


6) The prior art of record did not disclose or suggest an isolated polynucleotide encoding the amino acid sequence presented in SEQ ID NO:22 of the instant application.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

  
JOHN ULM  
PRIMARY EXAMINER  
GROUP 1800